Breakthrough Infections during Phase 1 and 2 Prime-Boost HIV-1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160.

Authors :: Lee, Deborah
Graham, Barney S.
Ya-Lin Chiu
Gilbert, Peter B.
McElrath, M. Juliana
Belshe, Robert B.
Buchbinder, Susan P.
Sheppard, Haynes W.
Koblin, Beryl A.
Mayer, Kenneth H.
Keefer, Michael C.
Mulligan, Mark J.
Celum, Connie L.
Source :: Journal of Infectious Diseases. 9/1/2004, Vol. 190 Issue 5, p903-907. 5p.
Publication Year :: 2004

Subjects :: *AIDS vaccines
*HIV infections
*HIV
*AIDS
*IMMUNE response
*T cells
*BREAKTHROUGH infections

Full Text Access

Tools